Literature DB >> 10909973

Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element.

G Skoglund1, M A Hussain, G G Holz.   

Abstract

Glucagon-like peptide 1 (GLP-1), a hormonal activator of adenyl cyclase, stimulates insulin gene transcription, an effect mediated by the cAMP response element (CRE) of the rat insulin I gene promoter (RIP1). Here we demonstrate that the signaling mechanism underlying stimulatory effects of GLP-1 on insulin gene transcription results from protein kinase A (PKA)-independent activation of the RIP1 CRE. Although GLP-1 stimulates cAMP production in rat INS-1 insulinoma cells, we find accompanying activation of a -410-bp RIP1 luciferase construct (-410RIP1-LUC) to exist independently of this second messenger. GLP-1 produced a dose-dependent stimulation of -410RIP1-LUC (EC50 0.43 nmol/l), an effect reproduced by the GLP-1 receptor agonist exendin-4 and abolished by the antagonist exendin(9-39). Activation of RIP1 by GLP-1 was not affected by cotransfection with dominant-negative Gs alpha, was not blocked by cAMP antagonist Rp-cAMPS, and was insensitive to PKA antagonist H-89. Truncation of -410RIP1-LUC to generate -307-, -206-, and -166-bp constructs revealed 2 segments of RIP1 targeted by GLP-1. The first segment, not regulated by forskolin, was located between -410 and -307 bp of the promoter. The second segment, regulated by both GLP-1 and forskolin, included the CRE and was located between -206 and -166 bp. Consistent with these observations, stimulatory effects of GLP-1 at RIP1 were reduced after introduction of delta-182 and delta-183/180 inactivating deletions at the CRE. The action of GLP-1 at -410RIP1-LUC was also reduced by cotransfection with A-CREB, a genetically engineered isoform of the CRE binding protein CREB, which dimerizes with and prevents binding of basic-region-leucine-zipper (bZIP) transcription factors to the CRE. In contrast, the action of GLP-1 at the CRE was not blocked by cotransfection with M1-CREB, an isoform that lacks a consensus serine residue serving as substrate for PKA-mediated phosphorylation. On the basis of these studies, it is proposed that PKA-independent stimulatory actions of GLP-1 at RIP1 are mediated by bZIP transcription factors related in structure but not identical to CREB.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10909973      PMCID: PMC3045812          DOI: 10.2337/diabetes.49.7.1156

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  58 in total

1.  cAMP analog antagonists of cAMP action.

Authors:  L H Botelho; J D Rothermel; R V Coombs; B Jastorff
Journal:  Methods Enzymol       Date:  1988       Impact factor: 1.600

2.  K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases.

Authors:  H Kase; K Iwahashi; S Nakanishi; Y Matsuda; K Yamada; M Takahashi; C Murakata; A Sato; M Kaneko
Journal:  Biochem Biophys Res Commun       Date:  1987-01-30       Impact factor: 3.575

3.  Glucose stimulation of the proinsulin synthesis in isolated pancreatic islets without increasing amount of proinsulin mRNA.

Authors:  N Itoh; T Sei; K Nose; H Okamoto
Journal:  FEBS Lett       Date:  1978-09-15       Impact factor: 4.124

4.  Insulin biosynthesis. I. On the mechanism of glucose stimulation.

Authors:  M A Permutt; D M Kipnis
Journal:  J Biol Chem       Date:  1972-02-25       Impact factor: 5.157

5.  Glucagon-like peptide-1 regulates the beta cell transcription factor, PDX-1, in insulinoma cells.

Authors:  X Wang; C M Cahill; M A Piñeyro; J Zhou; M E Doyle; J M Egan
Journal:  Endocrinology       Date:  1999-10       Impact factor: 4.736

6.  Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells.

Authors:  J Buteau; R Roduit; S Susini; M Prentki
Journal:  Diabetologia       Date:  1999-07       Impact factor: 10.122

7.  Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line.

Authors:  D J Drucker; J Philippe; S Mojsov; W L Chick; J F Habener
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

8.  Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells.

Authors:  Y Wang; J M Egan; M Raygada; O Nadiv; J Roth; C Montrose-Rafizadeh
Journal:  Endocrinology       Date:  1995-11       Impact factor: 4.736

9.  Calcium-mobilizing insulin secretagogues stimulate transcription that is directed by the cyclic adenosine 3',5'-monophosphate/calcium response element in a pancreatic islet beta-cell line.

Authors:  B Eckert; M Schwaninger; W Knepel
Journal:  Endocrinology       Date:  1996-01       Impact factor: 4.736

10.  Control of insulin gene expression in pancreatic beta-cells and in an insulin-producing cell line, RIN-5F cells. I. Effects of glucose and cyclic AMP on the transcription of insulin mRNA.

Authors:  D A Nielsen; M Welsh; M J Casadaban; D F Steiner
Journal:  J Biol Chem       Date:  1985-11-05       Impact factor: 5.157

View more
  35 in total

1.  Expression of cAMP-regulated guanine nucleotide exchange factors in pancreatic beta-cells.

Authors:  C A Leech; G G Holz; O Chepurny; J F Habener
Journal:  Biochem Biophys Res Commun       Date:  2000-11-11       Impact factor: 3.575

2.  Epac-selective cAMP analog 8-pCPT-2'-O-Me-cAMP as a stimulus for Ca2+-induced Ca2+ release and exocytosis in pancreatic beta-cells.

Authors:  Guoxin Kang; Jamie W Joseph; Oleg G Chepurny; Marie Monaco; Michael B Wheeler; Johannes L Bos; Frank Schwede; Hans-G Genieser; George G Holz
Journal:  J Biol Chem       Date:  2002-12-20       Impact factor: 5.157

Review 3.  Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.

Authors:  Marzieh Salehi; Benedikt A Aulinger; David A D'Alessio
Journal:  Endocr Rev       Date:  2008-02-21       Impact factor: 19.871

Review 4.  Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors:  Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

5.  Over-expression of the glucagon-like peptide-1 receptor on INS-1 cells confers autocrine stimulation of insulin gene promoter activity: a strategy for production of pancreatic beta-cell lines for use in transplantation.

Authors:  Oleg G Chepurny; George G Holz
Journal:  Cell Tissue Res       Date:  2002-01-08       Impact factor: 5.249

Review 6.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

7.  Regulation of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus at concentrations that inhibit calcineurin activity and involving the transcription factor CREB.

Authors:  Elke Oetjen; Daniela Grapentin; Roland Blume; Michael Seeger; Doris Krause; Anke Eggers; Willhart Knepel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-02-20       Impact factor: 3.000

Review 8.  New pharmacologic agents for diabetes.

Authors:  C J Bailey
Journal:  Curr Diab Rep       Date:  2001-10       Impact factor: 4.810

9.  cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca2+-induced Ca2+ release in INS-1 pancreatic beta-cells.

Authors:  G Kang; O G Chepurny; G G Holz
Journal:  J Physiol       Date:  2001-10-15       Impact factor: 5.182

10.  The impact of dietary energy intake on cognitive aging.

Authors:  Mark P Mattson
Journal:  Front Aging Neurosci       Date:  2010-03-08       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.